MacroGenics, Inc. - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

MacroGenics, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'MacroGenics, Inc. - Product Pipeline Review - 2015', provides an overview of the MacroGenics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of MacroGenics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of MacroGenics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of MacroGenics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the MacroGenics, Inc.'s pipeline products

Reason to Buy

- Evaluate MacroGenics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of MacroGenics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the MacroGenics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of MacroGenics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of MacroGenics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of MacroGenics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
MacroGenics, Inc. Snapshot 5
MacroGenics, Inc. Overview 5
Key Information 5
Key Facts 5
MacroGenics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
MacroGenics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
MacroGenics, Inc. - Pipeline Products Glance 13
MacroGenics, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
MacroGenics, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
MacroGenics, Inc. - Drug Profiles 16
margetuximab 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
teplizumab 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
enoblituzumab 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
MGD-006 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
MGD-007 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
MGD-010 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
MGD009 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Monoclonal Antibodies to Inhibit DR5 for Oncology 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MacroGenics, Inc. - Pipeline Analysis 27
MacroGenics, Inc. - Pipeline Products by Target 27
MacroGenics, Inc. - Pipeline Products by Route of Administration 28
MacroGenics, Inc. - Pipeline Products by Molecule Type 29
MacroGenics, Inc. - Pipeline Products by Mechanism of Action 30
MacroGenics, Inc. - Recent Pipeline Updates 31
MacroGenics, Inc. - Dormant Projects 35
MacroGenics, Inc. - Company Statement 36
MacroGenics, Inc. - Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables

MacroGenics, Inc., Key Information 5
MacroGenics, Inc., Key Facts 5
MacroGenics, Inc. - Pipeline by Indication, 2015 8
MacroGenics, Inc. - Pipeline by Stage of Development, 2015 9
MacroGenics, Inc. - Monotherapy Products in Pipeline, 2015 10
MacroGenics, Inc. - Out-Licensed Products in Pipeline, 2015 11
MacroGenics, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 12
MacroGenics, Inc. - Phase II, 2015 13
MacroGenics, Inc. - Phase I, 2015 14
MacroGenics, Inc. - Preclinical, 2015 15
MacroGenics, Inc. - Pipeline by Target, 2015 27
MacroGenics, Inc. - Pipeline by Route of Administration, 2015 28
MacroGenics, Inc. - Pipeline by Molecule Type, 2015 29
MacroGenics, Inc. - Pipeline Products by Mechanism of Action, 2015 30
MacroGenics, Inc. - Recent Pipeline Updates, 2015 31
MacroGenics, Inc. - Dormant Developmental Projects,2015 35
MacroGenics, Inc., Other Locations 41
MacroGenics, Inc., Subsidiaries 41